BioCentury | Jun 7, 2010
Strategy

J&J's Pulmonary Push

In a pair of deals last week, Johnson & Johnson doubled the number of compounds in its disclosed pipeline for respiratory diseases from four to eight, and it sounds like the pharma is still shopping....
BioCentury | Jul 10, 2008
Targets & Mechanisms

New Resolve in Inflammation

...of IL-23 and IL-17. Orexo is developing two classes of anti-inflammatory compounds- 15-lipoxygenase inhibitors and eoxin...
BioCentury | Feb 14, 2008
Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Pulmonary disease Asthma; rhinitis; chronic obstructive pulmonary disease (COPD) 15-lipoxygenase-1 pathway In vitro studies suggest that antagonizing the 15-lipoxygenase-1 pathway may be...
BioCentury | Jan 14, 2008
Clinical News

OX-2477: Phase I start

...healthy volunteers. Orexo AB (SSE:ORX), Uppsala, Sweden Product: OX-2477 Business: Inflammation Molecular target: Eoxin Description: Eoxin...
BioCentury | Nov 19, 2007
Company News

Biolipox, Orexo deal

...for asthma and chronic obstructive pulmonary disease (COPD), and BLX-Eoxin consists of a portfolio of eoxin...
...must be met by Dec. 31, 2009: out-licensing NLA cetirizine nasal spray, BLX-CLI or BLX- Eoxin...
BioCentury | Oct 22, 2007
Strategy

One deal at a time

...in Phase I to treat inflammation. ORX also would gain three preclinical programs from Biolipox: eoxin...
BioCentury | Oct 22, 2007
Company News

Biolipox, Orexo deal

...II testing to treat allergic and non-allergic rhinitis. ORX also would gain three preclinical programs: eoxin...
BioCentury | Oct 16, 2007
Company News

Orexo acquiring Biolipox

...Phase II testing for allergic and non-allergic rhinitis. ORX also would gain three preclinical programs: eoxin...
BioCentury | Jan 24, 2005
Tools & Techniques

Biolipox: Bypassing COX-2

...and also have been shown to be involved in inflammatory processes. The company believes that eoxin...
...pulmonary disease (COPD). Biolipox discovered eoxins and owns an extensive patent portfolio on eoxins and eoxin...
BioCentury | Jun 10, 2002
Emerging Company Profile

Biolipox: Arachidonic acid rocks

...inhibitors), and leukotriene receptor antagonists," Dalsgaard said. "So we are pretty convinced that our novel Eoxin...
...specific receptors." The pathway enzymes and products were discovered in eosinophilic cells, hence the name Eoxin...
...in the anti-inflammatory action of these compounds." Biolipox is developing an Eoxin-enzyme inhibitor and an Eoxin-receptor...
Items per page:
1 - 10 of 10